Gsk Plc Stock Current Ratio
G1SK34 Stock | BRL 42.80 1.00 2.28% |
GSK plc fundamentals help investors to digest information that contributes to GSK Plc's financial success or failures. It also enables traders to predict the movement of GSK Stock. The fundamental analysis module provides a way to measure GSK Plc's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GSK Plc stock.
GSK |
GSK plc Company Current Ratio Analysis
GSK Plc's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Competition |
In accordance with the recently published financial statements, GSK plc has a Current Ratio of 0.0 times. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers-General (which currently averages 0.0) industry. The current ratio for all Brazil stocks is 100.0% higher than that of the company.
Did you try this?
Run Commodity Directory Now
Commodity DirectoryFind actively traded commodities issued by global exchanges |
All Next | Launch Module |
GSK Fundamentals
Return On Equity | 0.31 | |||
Return On Asset | 0.0659 | |||
Profit Margin | 0.51 % | |||
Operating Margin | 0.25 % | |||
Current Valuation | 484.56 B | |||
Shares Outstanding | 4.09 B | |||
Price To Book | 2.60 X | |||
Price To Sales | 9.93 X | |||
Revenue | 34.11 B | |||
Gross Profit | 19.92 B | |||
EBITDA | 8.6 B | |||
Net Income | 4.38 B | |||
Total Debt | 19.76 B | |||
Book Value Per Share | 5.25 X | |||
Cash Flow From Operations | 7.95 B | |||
Earnings Per Share | 6.69 X | |||
Price To Earnings To Growth | 0.45 X | |||
Number Of Employees | 10 | |||
Beta | 0.28 | |||
Market Capitalization | 388.07 B | |||
Total Asset | 79.1 B | |||
Z Score | 11.4 | |||
Annual Yield | 0.04 % | |||
Net Asset | 79.1 B | |||
Last Dividend Paid | 0.61 |
About GSK Plc Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GSK plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GSK Plc using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GSK plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in GSK Stock
GSK Plc financial ratios help investors to determine whether GSK Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GSK with respect to the benefits of owning GSK Plc security.